Inactive Instrument

Tobira Therapeutics Inc Stock

Stocks

End-of-day quote Nasdaq
- ^USD	-

20/10/16	Tobira Therapeutics : Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting	BU
03/10/16	Tobira Therapeutics : Announces Presentations Related to Cenicriviroc’s Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting	BU
21/09/16	TBRA Brower Piven Commences An Investigation Into The Proposed Sale Of Tobira Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	BU
21/09/16	Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Tobira Therapeutics, Inc. to Allergan plc for $28.35 Per Share Is Fair to Shareholders	BU
20/09/16	TOBIRA PHARMACEUTICALS, INC. Rigrodsky & Long, P.A. Announces Investigation Of Buyout	BU

24/10/16	TOBIRA fait gagner plus de 40 000 euros à un investisseur !
20/09/16	Allergan achète Tobira, spécialiste du traitement de la Nash

Manager	Title	Age	Since
Robert Michael CEO	Chief Executive Officer	55	-
Scott Reents DFI	Director of Finance/CFO	59	-
Jennifer M. Lagunas SEC	Corporate Secretary	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+1.10%	-2.67%	+62.79%	+70.47%	67.53B
ARGENX SE	+1.28%	+8.71%	+13.96%	+95.16%	60.74B
LONZA GROUP AG	+0.36%	-0.95%	+20.09%	+99.04%	55.66B
BEONE MEDICINES AG	-0.96%	+7.41%	+10.20%	+108.91%	47.97B
IQVIA HOLDINGS INC.	-1.25%	+2.35%	+22.74%	+38.34%	45.24B
REVOLUTION MEDICINES, INC.	-2.41%	-0.73%	+167.89%	+794.72%	39.08B
CELLTRION, INC.	+1.21%	-2.56%	+20.27%	+52.81%	35.34B
GENMAB A/S	-0.87%	-2.89%	+79.60%	+63.96%	33.45B
INSMED INCORPORATED	-2.22%	+8.56%	-39.26%	+397.14%	26.49B
Average	-0.42%	+3.27%	+39.81%	+191.17%	46B
Weighted average by Cap.	-0.17%	+3.39%	+40.40%	+166.70%

Employees

Sector